Pacira Pharma (PCRX) Misses Q2 EPS by 35c

Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.53, $0.35 worse than the analyst estimate of $0.88. Revenue for the quarter came in at $169.4 million versus the consensus estimate of $172.22 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Sunstone Hotel Investors to sell Hyatt Regency San Francisco for $279M
• Prosperity Bancshares (PB) Reiterated at Overweight by Cantor Fitzgerald as Estimates Revised